TISIDB

Summary
Symbol	HMOX1
Name	heme oxygenase 1
Aliases	bK286B10; HO-1; heme oxygenase (decycling) 1; HMOX1D; HSP32; heat shock protein, 32-kD
Chromosomal Location	22q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Microsome Endoplasmic reticulum membrane Peripheral membrane protein Cytoplasmic side
Domain	PF01126 Heme oxygenase
Function	Heme oxygenase cleaves the heme ring at the alpha methene bridge to form biliverdin. Biliverdin is subsequently converted to bilirubin by biliverdin reductase. Under physiological conditions, the activity of heme oxygenase is highest in the spleen, where senescent erythrocytes are sequestrated and destroyed. Exhibits cytoprotective effects since excess of free heme sensitizes cells to undergo apoptosis.

> Gene Ontology [ TOP ]
Biological Process	GO:0000302 response to reactive oxygen species GO:0001525 angiogenesis GO:0001666 response to hypoxia GO:0001818 negative regulation of cytokine production GO:0001819 positive regulation of cytokine production GO:0001889 liver development GO:0001935 endothelial cell proliferation GO:0002246 wound healing involved in inflammatory response GO:0002262 myeloid cell homeostasis GO:0002263 cell activation involved in immune response GO:0002274 myeloid leukocyte activation GO:0002275 myeloid cell activation involved in immune response GO:0002279 mast cell activation involved in immune response GO:0002366 leukocyte activation involved in immune response GO:0002367 cytokine production involved in immune response GO:0002440 production of molecular mediator of immune response GO:0002443 leukocyte mediated immunity GO:0002444 myeloid leukocyte mediated immunity GO:0002448 mast cell mediated immunity GO:0002683 negative regulation of immune system process GO:0002685 regulation of leukocyte migration GO:0002686 negative regulation of leukocyte migration GO:0002694 regulation of leukocyte activation GO:0002695 negative regulation of leukocyte activation GO:0002697 regulation of immune effector process GO:0002698 negative regulation of immune effector process GO:0002699 positive regulation of immune effector process GO:0002700 regulation of production of molecular mediator of immune response GO:0002701 negative regulation of production of molecular mediator of immune response GO:0002703 regulation of leukocyte mediated immunity GO:0002704 negative regulation of leukocyte mediated immunity GO:0002718 regulation of cytokine production involved in immune response GO:0002719 negative regulation of cytokine production involved in immune response GO:0002886 regulation of myeloid leukocyte mediated immunity GO:0002887 negative regulation of myeloid leukocyte mediated immunity GO:0003012 muscle system process GO:0003013 circulatory system process GO:0003018 vascular process in circulatory system GO:0006778 porphyrin-containing compound metabolic process GO:0006787 porphyrin-containing compound catabolic process GO:0006788 heme oxidation GO:0006875 cellular metal ion homeostasis GO:0006879 cellular iron ion homeostasis GO:0006887 exocytosis GO:0006914 autophagy GO:0006979 response to oxidative stress GO:0007249 I-kappaB kinase/NF-kappaB signaling GO:0007584 response to nutrient GO:0007588 excretion GO:0008015 blood circulation GO:0008217 regulation of blood pressure GO:0008625 extrinsic apoptotic signaling pathway via death domain receptors GO:0008630 intrinsic apoptotic signaling pathway in response to DNA damage GO:0009266 response to temperature stimulus GO:0009408 response to heat GO:0009991 response to extracellular stimulus GO:0010035 response to inorganic substance GO:0010038 response to metal ion GO:0010039 response to iron ion GO:0010506 regulation of autophagy GO:0010508 positive regulation of autophagy GO:0010656 negative regulation of muscle cell apoptotic process GO:0010657 muscle cell apoptotic process GO:0010660 regulation of muscle cell apoptotic process GO:0014805 smooth muscle adaptation GO:0014806 smooth muscle hyperplasia GO:0014900 muscle hyperplasia GO:0016236 macroautophagy GO:0016239 positive regulation of macroautophagy GO:0016241 regulation of macroautophagy GO:0017157 regulation of exocytosis GO:0019439 aromatic compound catabolic process GO:0030336 negative regulation of cell migration GO:0031099 regeneration GO:0031100 animal organ regeneration GO:0031667 response to nutrient levels GO:0031668 cellular response to extracellular stimulus GO:0031669 cellular response to nutrient levels GO:0031670 cellular response to nutrient GO:0032386 regulation of intracellular transport GO:0032387 negative regulation of intracellular transport GO:0032418 lysosome localization GO:0032602 chemokine production GO:0032642 regulation of chemokine production GO:0032722 positive regulation of chemokine production GO:0032762 mast cell cytokine production GO:0032763 regulation of mast cell cytokine production GO:0032764 negative regulation of mast cell cytokine production GO:0033002 muscle cell proliferation GO:0033003 regulation of mast cell activation GO:0033004 negative regulation of mast cell activation GO:0033006 regulation of mast cell activation involved in immune response GO:0033007 negative regulation of mast cell activation involved in immune response GO:0033013 tetrapyrrole metabolic process GO:0033015 tetrapyrrole catabolic process GO:0034101 erythrocyte homeostasis GO:0034381 plasma lipoprotein particle clearance GO:0034383 low-density lipoprotein particle clearance GO:0034395 regulation of transcription from RNA polymerase II promoter in response to iron GO:0034599 cellular response to oxidative stress GO:0034605 cellular response to heat GO:0035094 response to nicotine GO:0035150 regulation of tube size GO:0036293 response to decreased oxygen levels GO:0036294 cellular response to decreased oxygen levels GO:0040013 negative regulation of locomotion GO:0042033 chemokine biosynthetic process GO:0042035 regulation of cytokine biosynthetic process GO:0042089 cytokine biosynthetic process GO:0042107 cytokine metabolic process GO:0042108 positive regulation of cytokine biosynthetic process GO:0042167 heme catabolic process GO:0042168 heme metabolic process GO:0042311 vasodilation GO:0042312 regulation of vasodilation GO:0042440 pigment metabolic process GO:0042542 response to hydrogen peroxide GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043279 response to alkaloid GO:0043299 leukocyte degranulation GO:0043300 regulation of leukocyte degranulation GO:0043301 negative regulation of leukocyte degranulation GO:0043303 mast cell degranulation GO:0043304 regulation of mast cell degranulation GO:0043305 negative regulation of mast cell degranulation GO:0043392 negative regulation of DNA binding GO:0043433 negative regulation of sequence-specific DNA binding transcription factor activity GO:0043500 muscle adaptation GO:0043523 regulation of neuron apoptotic process GO:0043524 negative regulation of neuron apoptotic process GO:0043618 regulation of transcription from RNA polymerase II promoter in response to stress GO:0043619 regulation of transcription from RNA polymerase II promoter in response to oxidative stress GO:0043620 regulation of DNA-templated transcription in response to stress GO:0043627 response to estrogen GO:0044057 regulation of system process GO:0044270 cellular nitrogen compound catabolic process GO:0045055 regulated exocytosis GO:0045073 regulation of chemokine biosynthetic process GO:0045080 positive regulation of chemokine biosynthetic process GO:0045576 mast cell activation GO:0045765 regulation of angiogenesis GO:0045766 positive regulation of angiogenesis GO:0045909 positive regulation of vasodilation GO:0045920 negative regulation of exocytosis GO:0046149 pigment catabolic process GO:0046685 response to arsenic-containing substance GO:0046686 response to cadmium ion GO:0046700 heterocycle catabolic process GO:0046916 cellular transition metal ion homeostasis GO:0048514 blood vessel morphogenesis GO:0048659 smooth muscle cell proliferation GO:0048660 regulation of smooth muscle cell proliferation GO:0048661 positive regulation of smooth muscle cell proliferation GO:0048662 negative regulation of smooth muscle cell proliferation GO:0048732 gland development GO:0048872 homeostasis of number of cells GO:0050673 epithelial cell proliferation GO:0050755 chemokine metabolic process GO:0050777 negative regulation of immune response GO:0050865 regulation of cell activation GO:0050866 negative regulation of cell activation GO:0050880 regulation of blood vessel size GO:0050900 leukocyte migration GO:0051048 negative regulation of secretion GO:0051051 negative regulation of transport GO:0051090 regulation of sequence-specific DNA binding transcription factor activity GO:0051098 regulation of binding GO:0051100 negative regulation of binding GO:0051101 regulation of DNA binding GO:0051186 cofactor metabolic process GO:0051187 cofactor catabolic process GO:0051259 protein oligomerization GO:0051260 protein homooligomerization GO:0051271 negative regulation of cellular component movement GO:0051402 neuron apoptotic process GO:0051640 organelle localization GO:0051656 establishment of organelle localization GO:0055072 iron ion homeostasis GO:0055076 transition metal ion homeostasis GO:0060627 regulation of vesicle-mediated transport GO:0061008 hepaticobiliary system development GO:0061082 myeloid leukocyte cytokine production GO:0070482 response to oxygen levels GO:0070997 neuron death GO:0071241 cellular response to inorganic substance GO:0071243 cellular response to arsenic-containing substance GO:0071248 cellular response to metal ion GO:0071276 cellular response to cadmium ion GO:0071281 cellular response to iron ion GO:0071453 cellular response to oxygen levels GO:0071456 cellular response to hypoxia GO:0071496 cellular response to external stimulus GO:0072718 response to cisplatin GO:0072719 cellular response to cisplatin GO:0090066 regulation of anatomical structure size GO:0090594 inflammatory response to wounding GO:0097006 regulation of plasma lipoprotein particle levels GO:0097191 extrinsic apoptotic signaling pathway GO:0097193 intrinsic apoptotic signaling pathway GO:0097421 liver regeneration GO:1901214 regulation of neuron death GO:1901215 negative regulation of neuron death GO:1901342 regulation of vasculature development GO:1901361 organic cyclic compound catabolic process GO:1901565 organonitrogen compound catabolic process GO:1902041 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1903305 regulation of regulated secretory pathway GO:1903306 negative regulation of regulated secretory pathway GO:1903522 regulation of blood circulation GO:1903524 positive regulation of blood circulation GO:1903531 negative regulation of secretion by cell GO:1904018 positive regulation of vasculature development GO:1904019 epithelial cell apoptotic process GO:1904035 regulation of epithelial cell apoptotic process GO:1904036 negative regulation of epithelial cell apoptotic process GO:1904705 regulation of vascular smooth muscle cell proliferation GO:1904706 negative regulation of vascular smooth muscle cell proliferation GO:1990267 response to transition metal nanoparticle GO:1990874 vascular smooth muscle cell proliferation GO:2000146 negative regulation of cell motility GO:2001233 regulation of apoptotic signaling pathway GO:2001234 negative regulation of apoptotic signaling pathway GO:2001236 regulation of extrinsic apoptotic signaling pathway GO:2001237 negative regulation of extrinsic apoptotic signaling pathway
Molecular Function	GO:0004392 heme oxygenase (decyclizing) activity GO:0004620 phospholipase activity GO:0004630 phospholipase D activity GO:0008081 phosphoric diester hydrolase activity GO:0016298 lipase activity GO:0016705 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0020037 heme binding GO:0042578 phosphoric ester hydrolase activity GO:0046906 tetrapyrrole binding
Cellular Component	GO:0005901 caveola GO:0044853 plasma membrane raft GO:0045121 membrane raft GO:0098589 membrane region GO:0098857 membrane microdomain

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04066 HIF-1 signaling pathway hsa04978 Mineral absorption hsa00860 Porphyrin and chlorophyll metabolism hsa01100 Metabolic pathways
Reactome	R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-189483: Heme degradation R-HSA-168256: Immune System R-HSA-6785807: Interleukin-4 and 13 signaling R-HSA-917937: Iron uptake and transport R-HSA-1430728: Metabolism R-HSA-189445: Metabolism of porphyrins R-HSA-449147: Signaling by Interleukins R-HSA-382551: Transmembrane transport of small molecules

Summary
Symbol	HMOX1
Name	heme oxygenase 1
Aliases	bK286B10; HO-1; heme oxygenase (decycling) 1; HMOX1D; HSP32; heat shock protein, 32-kD
Chromosomal Location	22q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between HMOX1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between HMOX1 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
26595750	Neuroblastoma	Inhibit immunity (T cell function)	Importantly, HO-1 inhibition abrogated immune cell paralysis affecting CD4 and CD8 T-effector cells.
28512172	Prostate Carcinoma	Inhibit immunity	In this study, we assessed how hemin, a pharmacologic inducer of heme oxygenase-1 (HO-1), has an impact on prostate cancer development in an in vivo conditioning model. Conditioning resulted in increased tumor latency and decreased initial growth rate. Histologic analysis of tumors grown in conditioned mice revealed impaired vascularization. Hemin-treated human umbilical vein endothelial cells (HUVEC) exhibited decreased tubulogenesis in vitro only in the presence of TRAMP-C1-conditioned media. In addition, hemin boosted CD8+ T-cell proliferation and degranulation in vitro and antigen-specific cytotoxicity in vivo A significant systemic increase in CD8+ T-cell frequency was observed in preconditioned tumor-bearing mice.
24778275	Lung Carcinoma; Pancreatic Ductal Adenocarcinoma	Inhibit immunity	A basis for the function of the FAP(+)/CD45(+) subset is shown to be the immune inhibitory enzyme, heme oxygenase-1 (HO-1). The FAP(+)/CD45(+) cells are the major tumoral source of HO-1, and an inhibitor of HO-1, Sn mesoporphyrin, causes the same extent of immune-dependent arrest of LL2/OVA tumor growth as does the depletion of these cells. Because this observation of immune suppression by HO-1 expressed by the FAP(+)/CD45(+) stromal cell is replicated in a transplanted model of pancreatic ductal adenocarcinoma, we conclude that pharmacologically targeting this enzyme may improve cancer immunotherapy.

Summary
Symbol	HMOX1
Name	heme oxygenase 1
Aliases	bK286B10; HO-1; heme oxygenase (decycling) 1; HMOX1D; HSP32; heat shock protein, 32-kD
Chromosomal Location	22q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of HMOX1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	HMOX1
Name	heme oxygenase 1
Aliases	bK286B10; HO-1; heme oxygenase (decycling) 1; HMOX1D; HSP32; heat shock protein, 32-kD
Chromosomal Location	22q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of HMOX1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.498	0.273
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.384	0.891
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.572	0.765
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.151	0.715
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.421	0.816
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.199	0.936
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.25	0.676
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.263	0.883
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.249	0.9
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.704	0.761
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.823	0.821
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.124	0.516

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of HMOX1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	7.7	-7.7	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	8.3	-8.3	1

Summary
Symbol	HMOX1
Name	heme oxygenase 1
Aliases	bK286B10; HO-1; heme oxygenase (decycling) 1; HMOX1D; HSP32; heat shock protein, 32-kD
Chromosomal Location	22q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HMOX1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	HMOX1
Name	heme oxygenase 1
Aliases	bK286B10; HO-1; heme oxygenase (decycling) 1; HMOX1D; HSP32; heat shock protein, 32-kD
Chromosomal Location	22q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HMOX1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HMOX1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	HMOX1
Name	heme oxygenase 1
Aliases	bK286B10; HO-1; heme oxygenase (decycling) 1; HMOX1D; HSP32; heat shock protein, 32-kD
Chromosomal Location	22q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HMOX1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	HMOX1
Name	heme oxygenase 1
Aliases	bK286B10; HO-1; heme oxygenase (decycling) 1; HMOX1D; HSP32; heat shock protein, 32-kD
Chromosomal Location	22q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of HMOX1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	HMOX1
Name	heme oxygenase 1
Aliases	bK286B10; HO-1; heme oxygenase (decycling) 1; HMOX1D; HSP32; heat shock protein, 32-kD
Chromosomal Location	22q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between HMOX1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	HMOX1
Name	heme oxygenase 1
Aliases	bK286B10; HO-1; heme oxygenase (decycling) 1; HMOX1D; HSP32; heat shock protein, 32-kD
Chromosomal Location	22q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting HMOX1 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting HMOX1.

ID	Name	Drug Type	Targets	#Targets
DB00157	NADH	Small Molecule	AASS, ACADS, ADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH7, AKR1B1, AKR1C1 ......	144
DB01942	Formic Acid	Small Molecule	ACYP2, CA2, CASK, CTBP1, CYTH2, FGF1, GGACT, GPHN, HMOX1, NOS1, PV ......	12
DB02073	Biliverdine IX Alpha	Small Molecule	BLVRB, HMOX1, MB	3
DB02468	12-Phenylheme	Small Molecule	HMOX1	1
DB03906	2-Phenylheme	Small Molecule	HMOX1	1
DB04803	Verdoheme	Small Molecule	HMOX1	1
DB04912	Stannsoporfin	Small Molecule	HMOX1, HMOX2	2
DB06914	1-({2-[2-(4-CHLOROPHENYL)ETHYL]-1,3-DIOXOLAN-2-YL}METHYL)-1H-IMIDAZOLE	Small Molecule	HMOX1	1
DB07342	1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone	Small Molecule	HMOX1	1

Browse HMOX1